Advertisement
U.S. markets closed

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.5300-0.1000 (-2.16%)
At close: 04:00PM EDT
4.5101 -0.02 (-0.44%)
After hours: 07:49PM EDT

MannKind Corporation

1 Casper Street
Danbury, CT 06810
United States
818 661 5000
https://www.mannkindcorp.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees411

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael E. Castagna Pharm.D.CEO & Director1.26MN/A1977
Mr. Steven B. BinderChief Financial Officer800.2kN/A1963
Dr. David B. Thomson J.D., Ph.D.Executive VP, General Counsel & Secretary798.53kN/A1967
Dr. Stuart A. Tross Ph.D.Executive VP and Chief People & Workplace Officer678.4kN/A1967
Mr. Sanjay Singh M.B.A.Executive Vice President of Technical Operations364.53kN/A1966
Ms. Lauren M. SabellaExecutive VP & COON/AN/A1961
Ms. Rosabel Realica AlinayaVP of Investor Relations & Treasury402.26kN/A1961
Mr. John F. BedardSenior Vice President of Worldwide Regulatory AffairsN/AN/A1950
Mr. James Patrick McCauley Jr., J.D., M.B.A.Chief Commercial Officer614.06kN/A1966
Dr. Burkhard Blank M.D.Executive VP of Research & Development and Chief Medical OfficerN/AN/A1955
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Corporate Governance

MannKind Corporation’s ISS Governance QualityScore as of March 1, 2024 is 3. The pillar scores are Audit: 6; Board: 3; Shareholder Rights: 4; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.